1 / 14

It's All About the Mitochondria: “Monogenic Mitochondrial Disorders” → NEJM, March 2012

It's All About the Mitochondria: “Monogenic Mitochondrial Disorders” → NEJM, March 2012. George Ngo, PharmD Candidate April 6, 2012 University of Georgia College of Pharmacy Class of 2012. Mitochondria are Key Players in. ATP. Generation of Ion homeostasis Innate immune responses

senona
Download Presentation

It's All About the Mitochondria: “Monogenic Mitochondrial Disorders” → NEJM, March 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. It's All About the Mitochondria: “Monogenic Mitochondrial Disorders” → NEJM, March 2012 George Ngo, PharmD Candidate April 6, 2012 University of Georgia College of Pharmacy Class of 2012

  2. Mitochondria are Key Players in... ATP • Generation of • Ion homeostasis • Innate immune responses • Production of reactive oxygen species (ROS) • Programmed cell death (apoptosis) • Adaptive thermogenesis

  3. Mitochondrial Structure

  4. Mitochondrial Structure

  5. When Mitochondria Go Bad... • Alzheimer's disease • Parkinson's disease • Cancer • Cardiac disease • Diabetes • Epilepsy • Huntington's disease • Obesity

  6. When Mitochondria Go Bad...

  7. Why Should We Care? • Progressive decline in the expression of mitochondrial genes is a central feature of normal human aging • It is unclear whether changes the mitochondrial genetic expression has positive or negative effects on life span • The aging of the population in developed societies and prevalence of previously mentioned diseases

  8. Antibiotics (ex. chloramphenicol) Chemotherapeutic agents (ex. doxorubicin) Inhaled anesthetics (ex. halothane) Environmental toxins RX Spotlight • Amiodarone • Aspirin • Metformin • Haloperidol • Statins • Valproic acid • Zidovudine

  9. New drugs are being studied in terms of: time and concentration at the cellular / mitochondrial level structure-activity relationships properties of “Mitochondrial Medicine” • Certain pts with mitochondrial disorders may be at higher risk of developing adverse reactions / side effects than healthy pts • Mitochondrial dysfunction can be one MOA of new drugs ADME

  10. Pharmaceutical Intervention • There are four strategies for intervening in mitochondrial dysfunction • Genetic therapy • Small molecules to target specific cellular sites • Metabolic manipulation • Diet and exercise

  11. Nutritional modulation affected mitochondrial fxn Cyclosporin A, a permeability transition-pore desensitizer → Mutations in mitochondrial permeability pore protein, Ullrich's congenital muscular dystrophy What's in the Pipeline? • Idebenone (CoQ10 variant) → Friedreich's ataxia*, Leber's hereditary optic neuropathy • Ketogenic diet → epileptic seizures in children with electron transport chain disorders *approved for use

  12. Pharmaceutical Intervention

  13. Pioglitazone → diabetes Human growth hormone → obesity Vitamin E → mitochondrial trifunctional protein deficiency More Mitochondria Involved... • Cyclosporin A → decreased size of myocardial infarcts during cardiac reperfusion • Nutritional therapy → diabetes

  14. References • Koopman WJ, Willems PH, Smeitlink JA. "Monogenic Mitochondrial Disorders." The New England Journal Of Medicine 366.12 (2012): 1132-41. MEDLINE with Full Text. Web. 06 April 2012.

More Related